Okuyama Y, Momota K, Morino A
Research Laboratories, Nippon Shinyaku Co., Ltd., Kyoto, Japan.
Arzneimittelforschung. 1997 Mar;47(3):276-84.
The pharmacokinetics of prulifloxacin ((+/-)-6-fluoro-1-methyl-7-[4-(5-methyl-2-oxo-1,3-dioxolen-4-yl) methyl-1-piperazinyl]-4-oxo-4H-[1,3]thiazeto[3,2-a]quinoline-3-car boxylic acid. CAS 123447-62-1, NM441), a quinolone antibacterial prodrug, was investigated after i.v. (14C-NM394, CAS 112984-60-8) or oral (14C-NM441) administration to rats, dogs and monkeys. 1. 14C-NM441 was absorbed mainly from the upper small intestine and then metabolized to NM394 partly in the intestinal membrane but mainly in the portal blood and liver. Thus NM441 was not detected in the systemic circulation. 2. After i.v. administration of 14C-NM394 (5 mg/kg), the plasma concentration of radioactivity decreased biexponentially, and the elimination half-life in rats, dogs and monkeys was 4.2, 5.8 and 7.0 h, respectively. After oral administration of 14C-NM441 (20 mg/kg), the plasma concentration of radioactivity reached a maximum at 0.7-3.3 h, and thereafter decreased as observed after i.v. administration of 14C-NM394. An effect of food on the absorption of NM441 was found. No clear sex-related differences were observed in the plasma concentration profiles of rats. 3. The concentration of radioactivity in most tissues of rats reached a maximum within 1 h after oral administration of 14C-NM441 and thereafter decreased along with the plasma concentration. At 0.5 h, the radioactivity concentrations were highest in the liver and kidney, moderately high in the spleen, pancreas, lung and mandibular gland and extremely low in the cerebrum and cerebellum. 4. The radioactivity in the excreta collected over a 96-h period was 96-98% of the oral dose (urine, 22-32%; feces, 64-75%) in rats, dogs and monkeys, 35% of the radioactivity administered was excreted in the bile of rats during a 48-h period after oral administration, and only a small portion of the biliary radioactivity was reabsorbed. 5. The proportion of 14C-NM394 that bound to serum proteins in vitro in rats, dogs, monkeys and humans was 41-59% in a concentration range of 0.1-10 micrograms/ml.
普利沙星((+/-)-6-氟-1-甲基-7-[4-(5-甲基-2-氧代-1,3-二氧戊环-4-基)甲基-1-哌嗪基]-4-氧代-4H-[1,3]噻嗪并[3,2-a]喹啉-3-羧酸,CAS 123447-62-1,NM441)是一种喹诺酮类抗菌前体药物,在对大鼠、狗和猴子静脉注射(14C-NM394,CAS 112984-60-8)或口服(14C-NM441)后,对其药代动力学进行了研究。1. 14C-NM441主要从小肠上段吸收,然后部分在肠膜中代谢为NM394,但主要在门静脉血和肝脏中代谢。因此,在体循环中未检测到NM441。在大鼠、狗和猴子中分别为4.2、5.8和7.0小时。口服14C-NM441(20 mg/kg)后,放射性血浆浓度在0.7 - 3.3小时达到最大值,此后如静脉注射14C-NM394后观察到的那样下降。发现食物对NM441的吸收有影响。在大鼠的血浆浓度曲线中未观察到明显的性别相关差异。3. 口服14C-NM441后,大鼠大多数组织中的放射性浓度在1小时内达到最大值,此后随血浆浓度下降。在0.5小时时,肝脏和肾脏中的放射性浓度最高,脾脏、胰腺、肺和下颌腺中的放射性浓度中等,大脑和小脑中的放射性浓度极低。4. 在大鼠、狗和猴子中,96小时收集的排泄物中的放射性为口服剂量的96 - 98%(尿液中为22 - 32%;粪便中为64 - 75%),口服给药后48小时内,大鼠胆汁中排出了35%的给药放射性,并且只有一小部分胆汁放射性被重吸收。5. 在大鼠、狗、猴子和人类中,在0.1 - 10微克/毫升的浓度范围内,体外与血清蛋白结合的14C-NM394的比例为41 - 59%。